Pfizenmaier K - Search Results

1

Enforced covalent trimerization increases the activity of the TNF ligand family members TRAIL and CD95L.

Berg D, Lehne M, Müller N, Siegmund D, Münkel S, Sebald W, Pfizenmaier K, Wajant H. Berg D, et al. Among authors: pfizenmaier k. Cell Death Differ. 2007 Dec;14(12):2021-34. doi: 10.1038/sj.cdd.4402213. Epub 2007 Aug 17. Cell Death Differ. 2007. PMID: 17703232

2

Activity of soluble OX40 ligand is enhanced by oligomerization and cell surface immobilization.

Müller N, Wyzgol A, Münkel S, Pfizenmaier K, Wajant H. Müller N, et al. Among authors: pfizenmaier k. FEBS J. 2008 May;275(9):2296-304. doi: 10.1111/j.1742-4658.2008.06382.x. Epub 2008 Apr 3. FEBS J. 2008. PMID: 18397322 Free article.

3

Activation of CD95L fusion protein prodrugs by tumor-associated proteases.

Watermann I, Gerspach J, Lehne M, Seufert J, Schneider B, Pfizenmaier K, Wajant H. Watermann I, et al. Among authors: pfizenmaier k. Cell Death Differ. 2007 Apr;14(4):765-74. doi: 10.1038/sj.cdd.4402051. Epub 2006 Oct 20. Cell Death Differ. 2007. PMID: 17053806

4

Tumor therapeutics by design: targeting and activation of death receptors.

Wajant H, Gerspach J, Pfizenmaier K. Wajant H, et al. Among authors: pfizenmaier k. Cytokine Growth Factor Rev. 2005 Feb;16(1):55-76. doi: 10.1016/j.cytogfr.2004.12.001. Cytokine Growth Factor Rev. 2005. PMID: 15733832 Review.

5

The extracellular domains of FasL and Fas are sufficient for the formation of supramolecular FasL-Fas clusters of high stability.

Henkler F, Behrle E, Dennehy KM, Wicovsky A, Peters N, Warnke C, Pfizenmaier K, Wajant H. Henkler F, et al. Among authors: pfizenmaier k. J Cell Biol. 2005 Mar 28;168(7):1087-98. doi: 10.1083/jcb.200501048. J Cell Biol. 2005. PMID: 15795317 Free PMC article.

6

A CD40-CD95L fusion protein interferes with CD40L-induced prosurvival signaling and allows membrane CD40L-restricted activation of CD95.

Assohou-Luty C, Gerspach J, Siegmund D, Müller N, Huard B, Tiegs G, Pfizenmaier K, Wajant H. Assohou-Luty C, et al. Among authors: pfizenmaier k. J Mol Med (Berl). 2006 Sep;84(9):785-97. doi: 10.1007/s00109-006-0073-1. Epub 2006 Aug 4. J Mol Med (Berl). 2006. PMID: 16924474

7

Death ligands designed to kill: development and application of targeted cancer therapeutics based on proapoptotic TNF family ligands.

Gerspach J, Wajant H, Pfizenmaier K. Gerspach J, et al. Among authors: pfizenmaier k. Results Probl Cell Differ. 2009;49:241-73. doi: 10.1007/400_2008_22. Results Probl Cell Differ. 2009. PMID: 19142623 Review.

8

Trimer stabilization, oligomerization, and antibody-mediated cell surface immobilization improve the activity of soluble trimers of CD27L, CD40L, 41BBL, and glucocorticoid-induced TNF receptor ligand.

Wyzgol A, Müller N, Fick A, Munkel S, Grigoleit GU, Pfizenmaier K, Wajant H. Wyzgol A, et al. Among authors: pfizenmaier k. J Immunol. 2009 Aug 1;183(3):1851-61. doi: 10.4049/jimmunol.0802597. Epub 2009 Jul 13. J Immunol. 2009. PMID: 19596991

9

Superior serum half life of albumin tagged TNF ligands.

Müller N, Schneider B, Pfizenmaier K, Wajant H. Müller N, et al. Among authors: pfizenmaier k. Biochem Biophys Res Commun. 2010 Jun 11;396(4):793-9. doi: 10.1016/j.bbrc.2010.04.134. Epub 2010 May 4. Biochem Biophys Res Commun. 2010. PMID: 20447380

10

Engineering death receptor ligands for cancer therapy.

Wajant H, Gerspach J, Pfizenmaier K. Wajant H, et al. Among authors: pfizenmaier k. Cancer Lett. 2013 May 28;332(2):163-74. doi: 10.1016/j.canlet.2010.12.019. Epub 2011 Jan 14. Cancer Lett. 2013. PMID: 21236560 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

251 results

Search Page

Filters